ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 58 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 2.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,800,000 | -36.1% | 1,000,000 | 0.0% | 0.64% | -37.3% |
| Q2 2023 | $7,510,000 | +10.8% | 1,000,000 | -33.3% | 1.02% | +5.3% |
| Q1 2023 | $6,780,000 | -74.4% | 1,500,000 | -36.2% | 0.97% | -68.7% |
| Q4 2022 | $26,479,992 | -6.9% | 2,349,600 | -20.9% | 3.10% | -11.3% |
| Q3 2022 | $28,436,000 | +12.1% | 2,971,352 | -5.3% | 3.50% | -24.9% |
| Q2 2022 | $25,373,000 | -50.1% | 3,136,352 | +4.2% | 4.66% | -29.4% |
| Q1 2022 | $50,892,000 | -18.5% | 3,011,352 | +3.6% | 6.60% | +2.4% |
| Q4 2021 | $62,458,000 | -73.2% | 2,906,352 | -7.9% | 6.44% | -61.7% |
| Q3 2021 | $233,175,000 | +35.1% | 3,156,981 | 0.0% | 16.81% | +15.9% |
| Q2 2021 | $172,624,000 | -25.8% | 3,156,981 | 0.0% | 14.51% | -36.1% |
| Q1 2021 | $232,796,000 | -14.5% | 3,156,981 | 0.0% | 22.72% | -2.6% |
| Q4 2020 | $272,132,000 | +129.9% | 3,156,981 | +0.6% | 23.33% | +54.0% |
| Q3 2020 | $118,390,000 | – | 3,136,981 | – | 15.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $715,272,000 | 67.97% |
| Logos Global Management LP | 3,156,981 | $232,796,000 | 22.72% |
| Vivo Capital, LLC | 4,220,048 | $311,186,000 | 10.94% |
| Foresite Capital Management IV, LLC | 785,945 | $57,956,000 | 6.94% |
| Foresite Capital Management V, LLC | 320,000 | $23,597,000 | 6.94% |
| Board of Trustees of The Leland Stanford Junior University | 518,822 | $38,258,000 | 3.38% |
| Cormorant Asset Management, LP | 881,770 | $65,022,000 | 1.45% |
| Redmile Group, LLC | 978,600 | $72,162,000 | 1.02% |
| SPHERA FUNDS MANAGEMENT LTD. | 130,351 | $9,612,000 | 0.74% |
| Artal Group S.A. | 525,000 | $38,714,000 | 0.68% |